| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000Ka 4500 |
| 001 |
in00002697613 |
| 005 |
20210727155726.0 |
| 006 |
m d |
| 007 |
cr cn| |
| 008 |
110602s2011 gw a ob 001 0 eng d |
| 020 |
|
|
|a 3642172148 (electronic bk.)
|
| 020 |
|
|
|a 9783642172144 (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)728098331
|
| 035 |
|
|
|a (OCoLC)ocn728098331
|
| 035 |
|
|
|a 3884237
|
| 037 |
|
|
|a 978-3-642-17213-7
|b Springer
|n http://www.springerlink.com
|
| 040 |
|
|
|a GW5XE
|b eng
|c GW5XE
|d OCLCQ
|d UtOrBLW
|
| 049 |
|
|
|a TXAC
|
| 050 |
|
4 |
|a RC662.18
|b .D53 2011
|
| 060 |
|
4 |
|a W1
|b HA51L v.203 2011
|
| 060 |
|
4 |
|a WK 815
|
| 082 |
0 |
4 |
|a 616.4/624
|2 22
|
| 245 |
0 |
0 |
|a Diabetes :
|b perspectives in drug therapy /
|c Mathias Schwanstecher, editor.
|
| 264 |
|
1 |
|a Heidelberg [Germany] ;
|a New York [N.Y.] :
|b Springer-Verlag,
|c [2011]
|
| 264 |
|
4 |
|c ©2011
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Handbook of experimental pharmacology,
|x 0171-2004 ;
|v v. 203
|
| 500 |
|
|
|a Electronic resource.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
|
|a Targeting type 2 diabetes -- Dual acting and pan-PPAR activators as potential anti-diabetic therapies -- GLP-1 agonists and dipeptidyl-peptidase IV inhibitors -- Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes -- SGLT inhibitors as new therapeutic tools in the treatment of diabetes -- Inhibitors of 11[beta]-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy -- Nampt and its potential role in inflammation and type 2 diabetes -- Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance -- Overcoming insulin resistance with ciliary neurotrophic factor -- Thermogenesis and related metabolic targets in anti-diabetic therapy -- Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes -- Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes -- AMP-activated protein kinase and metabolic control -- Mitochondria as potential targets in antidiabetic therapy -- Research and development of glucokinase activators for diabetes therapy : theoretical and practical aspects.
|
| 588 |
|
|
|a Description based on print version record.
|
| 650 |
1 |
2 |
|a Diabetes Mellitus, Type 2
|x drug therapy.
|0 https://id.nlm.nih.gov/mesh/D003924Q000188
|
| 650 |
2 |
2 |
|a Adiposity.
|0 https://id.nlm.nih.gov/mesh/D050154
|
| 650 |
2 |
2 |
|a Drug Discovery.
|0 https://id.nlm.nih.gov/mesh/D055808
|
| 650 |
|
0 |
|a Non-insulin-dependent diabetes
|x Treatment.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Schwanstecher, Mathias,
|d 1960-
|0 http://id.loc.gov/authorities/names/no2011059777
|
| 776 |
0 |
8 |
|i Print version:
|t Diabetes.
|d Heidelberg [Germany] ; New York [N.Y.] : Springer-Verlag, c2011
|z 9783642172137
|w (DLC) 2011923422
|w (OCoLC)690089339
|
| 830 |
|
0 |
|a Handbook of experimental pharmacology ;
|v v. 203.
|0 http://id.loc.gov/authorities/names/n42012274
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://dx.doi.org/10.1007/978-3-642-17214-4
|z Connect to the full text of this electronic book
|t 0
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
|
|
|a MARS
|
| 999 |
f |
f |
|s a49a2b7e-efde-39c9-8f4e-f5b4937bc0b8
|i a9838f09-7f91-3fe1-a7f1-b54c9483a83a
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|d Available Online
|t 0
|e RC662.18 .D53 2011
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC662.18 .D53 2011
|t 0
|l Available Online
|